News

The Biden Cancer Initiative has named Kim Thiboldeaux, the CEO of Cancer Support Community, to its Board of Directors.

A recent study has shown that the cancer risks for women with BRCA1 and BRCA2 mutations depend on the extent of the woman’s family history of cancer and the position of the specific fault within the gene.

The FDA has approved the dabrafenib/trametinib combination for patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC)

As the Senate revealed their healthcare reconciliation bill, healthcare advocacy and profession organizations weighed in.

The FDA has approved subcutaneous rituxumab (Rituxan Hycela) for the treatment of adults with previously untreated

The use of standard criteria for palliative care consultations in patients with advanced cancer is associated with an improvement in the quality of oncology care, as well as a reduction in downstream healthcare utilization.

The Insitute for Clinical Immuno-Oncology (ICLIO) are supporting multidisciplinary cancer teams to better deliver new and emerging cancer therapies.

The Association of Community Cancer Centers has lauched a financial advocacy boot camp offering free comprehensive online training for oncology financial advocates.

National Leiomyosarcoma Foundation joins Pattern.org in an effort to collect tumor tissue form patients with rare cancers.

National Leiomyosarcoma Foundation has collaborated to bring resources to family, caregivers and patients with leiomyosarcoma.

Regina Cunningham, PhD, RN, NEA-BC, FAAN, discusses her career journey, which led her to become CEO of the Hospital of the University of Pennsylvania, and shares insights on how nurses can leverage their unique skills to assume leadership roles in healthcare.

ASCO has released its Clinical Practice Guidelines as an app so clinicians can keep important information at their fingertips.

Daratumumab (Darzalex) has been approved for use in combination with pomalidomide (pomalyst) and dexamethasone for patients with multiple myeloma.

Expert Ilana Cass, MD, explains the options that women with have when it comes to preventing ovarian cancer.

Communication is key when it comes to discussing genetic information and hereditary cancers with family members.

A recent study looked at the long-term health-related effects of treatment for patients with localized prostate cancer, finding that some can continue for more than 10 years after treatment.

Adjuvant pertuzumab may help some early breast cancer patients.

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

The PARP inhibitor olaparib (Lynparza) was shown to reduce the risk of disease progression by 42% compared to standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer.

A recent study has found that a topical nail bed balm may be effective in preventing and mitigating nail damage, a common adverse effect from taxane chemotherapy.

By developing a training program, nurses in radiation at Johns Hopkins Hospital were able to eliminate the use of anasthesia for pediatric patients.

The novel psychological intervention, called CALM, has been shown to alleviate the distress of patients with advanced cancer.

The incidence of prostate cancer is 60% in black men in the US than in white men, and they are twice as likely to die from the disease.

As the intensity of treatments for childhood cancer drop, so does the rate of severe long-term side effects in these patients.

Patients new diagnosed with cancer were able to improve quality of life and distress by through a web-based stress management program.

According to findings presented at the 2017 ASCO Annual Meeting, earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by 40% for men with high-risk advanced or metastatic prostate cancer.

A recent study presented at the 2017 ASCO Annual Meeting found that breast cancer survivors who became pregnant had no greater risk of recurrence or death than women who underwent breast cancer treatment but did not become pregnant.

As presented at the 2017 ASCO Annual Meeting, adding abemaciclib to fulvestrant can reduce the risk of disease progression or death by 45% compared to fulvestrant alone in pretreated patients with HR+/HER2-negative breast cancer.

According to findings presented at the 2017 ASCO Annual Meeting, patients with low-risk advanced colon cancer would benefit from a reduction in chemotherapy post-surgery, without increasing risk of recurrence, to reduce risk of neuropathy.